SCHEMBL1573640

SCHEMBL1573640

CCC(CC)N(O)C(=O)Nc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MTOR P42345 2/20 0.49
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NPY5R Q15761 1/20 0.48
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
NOX1 Q9Y5S8 1/20 0.46
HSD17B10 Q99714 2/20 0.46
KLK7 P49862 1/20 0.46
NAPRT Q6XQN6 1/20 0.46
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX15 P16050 1/20 0.45
GAA P10253 1/20 0.45
TP53 P04637 1/20 0.44
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8101940 0.91 NPY5R (0.44) MEN1KMT2ANPSR1NPY5RNPC1
SCHEMBL7608699 0.91 MEN1 (0.49) MEN1KMT2AMTORALDH1A1NPSR1
SCHEMBL7612777 0.91 SLC1A3 (0.49) MEN1KMT2AALDH1A1NPY5RKDM4E
SCHEMBL7615446 0.88 SLC1A3 (0.51) MEN1KMT2AMTORALDH1A1NPSR1
SCHEMBL7615411 0.88 SMN1; SMN2 (0.61) MEN1KMT2AALDH1A1NPSR1NPY5R
SCHEMBL7613037 0.88 NPY5R (0.65) ALDH1A1NPY5RNPC1RAB9ASMN1; SMN2
SCHEMBL7610023 0.87 MEN1 (0.51) MEN1KMT2AMTORALDH1A1NPSR1
SCHEMBL7611785 0.85 NPY5R (0.57) MEN1KMT2AMTORALDH1A1NPSR1
SCHEMBL7612429 0.84 MITF (0.56) MEN1KMT2AALDH1A1NPY5RNPC1
SCHEMBL8103580 0.83 NPY5R (0.56) ALDH1A1NPY5RL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1699847-B1 METHOD FOR THE PREPARATION OF MEDICINAL COMPOSITIONS 3M INNOVATIVE PROPERTIES CO (US) 2011-04-13 EP claimed
US-7687054-B2 Biocompatible compounds for sustained release pharmaceutical drug delivery systems 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-03-30 US claimed
US-7597897-B2 Medicinal compositions and method for the preparation thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-10-06 US claimed
US-20080267885-A1 Medicinal Compositions and Method for the Preparation Thereof 3M INNOVATIVE PROPERTIES COMPANY 2008-10-30 US claimed
EP-1815845-A2 Biocompatible compounds for pharmaceutical drug delivery systems MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2007-08-08 EP claimed
EP-1014944-B1 BIOCOMPATIBLE COMPOUNDS FOR PHARMACEUTICAL DRUG DELIVERY SYSTEMS MINNESOTA MINING & MFG (US) 2007-04-11 EP claimed
CN-1902254-A Medicinal compositions and method for the preparation thereof 3M INNOVATIVE PROPERTIES CO (US) 2007-01-24 CN claimed
EP-1699847-A1 MEDICINAL COMPOSITIONS AND METHOD FOR THE PREPARATION THEREOF 3M Innovative Properties Company (US) 2006-09-13 EP claimed
US-20060002995-A1 Pharmaceutical porous particles ADAGIT (SE) 2006-01-05 US claimed
EP-1569626-A1 PHARMACEUTICAL POROUS PARTICLES Adagit (SE) 2005-09-07 EP claimed
EP-0777471-B1 INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES MINNESOTA MINING & MFG (US) 2002-11-27 EP claimed
US-20020164290-A1 Biocompatible compounds for sustained release pharmaceutical drug delivery systems 3M INNOVATIVE PROPERTIES COMPANY 2002-11-07 US claimed
US-6416742-B1 DISSOLVED POLYLACTONE, POLYTHIOESTER, OR POLYLACTAM AND FLUOROCARBON PROPELLANT; BIODEGRADABLE POLYMER STABILIZES AND SOLUBILIZES THE DRUG; SUSTAINED RELEASE 3M INNOVATIVE PROPERTIES COMPANY 2002-07-09 US claimed
US-6126919-A METERED DOSE INHALER FOR SUSTAINED RELEASE 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-10-03 US claimed
EP-1014944-A2 BIOCOMPATIBLE COMPOUNDS FOR PHARMACEUTICAL DRUG DELIVERY SYSTEMS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2000-07-05 EP claimed
CN-1246790-A Biocompatible compounds for pharmaceutical drug delivery systems MINNESOTA MINING & MFG (US) 2000-03-08 CN claimed
WO-1998034596-A2 BIOCOMPATIBLE COMPOUNDS FOR PHARMACEUTICAL DRUG DELIVERY SYSTEMS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-08-13 WO claimed
EP-0777471-A1 INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-06-11 EP claimed
US-5612377-A OXYUREA DERIVATIVE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-03-18 US claimed
WO-1996003983-A1 INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080267885-A1 Medicinal Compositions and Method for the Preparation Thereof CA7, ADCY1, CA12 MEN1 1139/4885KMT2A 3330/4885MTOR 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.